Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-EDGE Head-to-Head: Grazoprevir/Elbasvir vs SOF+PR in Chronic HCV
NCT02358044Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of grazoprevir, elbasvir in hepatitis C (HCV), sponsored by Merck & Co.. Started Feb 2015; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02358044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358044.